Recursion Pharmaceuticals Inc
RXRX5.090USD
-0.430-7.79%
Handelsschluss 08/19, 16:00（ET）Kurse um 15 Minuten verzögert
2.20BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Recursion Pharmaceuticals Inc Unternehmen
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Unternehmensinformationen
BörsenkürzelRXRX
Name des UnternehmensRecursion Pharmaceuticals Inc
IPO-datumApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Anzahl der mitarbeiter840
WertpapierartOrdinary Share
GeschäftsjahresendeApr 16
Addresse41S Rio Grande Street
StadtSALT LAKE CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl84101
Telefon13852690203
Websitehttps://www.recursion.com/
BörsenkürzelRXRX
IPO-datumApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
9.48M
63.99%
United Kingdom
5.34M
36.01%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Andere
69.16%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Andere
69.16%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.79%
Investment Advisor/Hedge Fund
10.49%
Venture Capital
7.26%
Sovereign Wealth Fund
3.78%
Individual Investor
2.94%
Hedge Fund
1.96%
Corporation
1.80%
Research Firm
1.73%
Bank and Trust
0.83%
Andere
25.42%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
32.23M
8.06%
-1.74M
-5.12%
Mar 31, 2025
ARK Investment Management LLC
34.82M
8.71%
+2.47M
+7.63%
Mar 31, 2025
Baillie Gifford & Co.
24.39M
6.1%
-471.04K
-1.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.07M
5.02%
-234.35K
-1.15%
Mar 31, 2025
SB Global Advisers Ltd
14.67M
3.67%
--
--
Mar 31, 2025
Kinnevik AB
13.43M
3.36%
+1.53M
+12.84%
Mar 31, 2025
Mubadala Investment Company PJSC
12.99M
3.25%
--
--
Mar 31, 2025
State Street Global Advisors (US)
13.09M
3.27%
+506.90K
+4.03%
Mar 31, 2025
Novo Holdings A/S
9.67M
2.42%
-449.50K
-4.44%
Mar 31, 2025
MIC Capital Management UK LLP
9.64M
2.41%
-1.00
-0.00%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
ARK Genomic Revolution ETF
5.68%
First Trust Nasdaq AI and Robotics ETF
2.38%
ARK Innovation ETF
1.41%
Franklin Genomic Advancements ETF
1.41%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
WisdomTree BioRevolution Fund
0.76%
AXS Green Alpha ETF
0.73%
SPDR S&P Biotech ETF
0.53%
WisdomTree Artificial Intelligence and Innov Fund
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil5.68%
First Trust Nasdaq AI and Robotics ETF
Anteil2.38%
ARK Innovation ETF
Anteil1.41%
Franklin Genomic Advancements ETF
Anteil1.41%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.88%
WisdomTree BioRevolution Fund
Anteil0.76%
AXS Green Alpha ETF
Anteil0.73%
SPDR S&P Biotech ETF
Anteil0.53%
WisdomTree Artificial Intelligence and Innov Fund
Anteil0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.34%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
